Partner Therapeutics’ Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Posted on by

Treatment will be Marketed by Nobelpharma Co. Ltd. Under the Trade Name Sargmalin® PMDA Approval of Sargmalin is the first regulatory approval of an inhaled recombinant GM-CSF product for aPAP LEXINGTON, Mass., April 3, 2024 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced that…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.